DK0666751T3 - Mutanter af hepatitis A-virus, stamme HM-175, til anvendelse som hepatitis A-vacciner - Google Patents

Mutanter af hepatitis A-virus, stamme HM-175, til anvendelse som hepatitis A-vacciner

Info

Publication number
DK0666751T3
DK0666751T3 DK93921524T DK93921524T DK0666751T3 DK 0666751 T3 DK0666751 T3 DK 0666751T3 DK 93921524 T DK93921524 T DK 93921524T DK 93921524 T DK93921524 T DK 93921524T DK 0666751 T3 DK0666751 T3 DK 0666751T3
Authority
DK
Denmark
Prior art keywords
hepatitis
vaccines
strain
hav
virus mutants
Prior art date
Application number
DK93921524T
Other languages
English (en)
Inventor
Ann W Funkhouser
Suzanne U Emerson
Robert H Purcell
Hondt Eric D
Original Assignee
Smithkline Beecham Biolog
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25485989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0666751(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Biolog, Us Health filed Critical Smithkline Beecham Biolog
Application granted granted Critical
Publication of DK0666751T3 publication Critical patent/DK0666751T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32421—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32432—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK93921524T 1992-09-18 1993-09-17 Mutanter af hepatitis A-virus, stamme HM-175, til anvendelse som hepatitis A-vacciner DK0666751T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94733892A 1992-09-18 1992-09-18
PCT/US1993/008610 WO1994006446A1 (en) 1992-09-18 1993-09-17 Hepatitis a virus vaccines

Publications (1)

Publication Number Publication Date
DK0666751T3 true DK0666751T3 (da) 2001-11-12

Family

ID=25485989

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93921524T DK0666751T3 (da) 1992-09-18 1993-09-17 Mutanter af hepatitis A-virus, stamme HM-175, til anvendelse som hepatitis A-vacciner

Country Status (14)

Country Link
US (4) US6180110B1 (da)
EP (1) EP0666751B1 (da)
JP (1) JP3523646B2 (da)
AT (1) ATE205536T1 (da)
AU (1) AU687012B2 (da)
CA (1) CA2144317C (da)
DE (1) DE69330758T2 (da)
DK (1) DK0666751T3 (da)
ES (1) ES2164074T3 (da)
HK (1) HK1013667A1 (da)
NZ (1) NZ256278A (da)
PT (1) PT666751E (da)
SG (1) SG73999A1 (da)
WO (1) WO1994006446A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
US6368602B1 (en) * 2000-06-16 2002-04-09 Hadasit Medical Research Services And Development Ltd Mucosal immunization against hepatitis A virus (HAV) through rectal administration of HAV vaccine
GB0304799D0 (en) 2003-03-03 2003-04-09 Glaxosmithkline Biolog Sa Novel method
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
EP1771585B1 (en) * 2004-07-13 2012-09-26 Gen-Probe Incorporated Compositions and methods for detection of hepatitis a virus nucleic acid
EP1915454A2 (en) * 2005-06-28 2008-04-30 The Government of the United States of America, represented by the Secretary, Department of Health and Human Services Growth of wild-type hepatitis a virus in cell culture
WO2007134250A2 (en) * 2006-05-12 2007-11-22 Goldengate Software, Inc. Method for forming homogeneous from heterogeneous data
CN102482666B (zh) 2009-07-06 2017-02-08 变异生物技术公司 制备囊泡的方法和由其产生的制剂
US9907746B2 (en) 2009-07-06 2018-03-06 Variation Biotechnologies, Inc. Methods for preparing vesicles and formulations produced therefrom
CN103096922B (zh) 2010-07-06 2019-08-06 变异生物技术公司 用于治疗流行性感冒的组合物和方法
CN102174477B (zh) * 2010-12-28 2012-11-21 深圳康泰生物制品股份有限公司 甲型肝炎病毒株sh及其二倍体细胞适应方法
MX359103B (es) 2011-01-13 2018-09-14 Variation Biotechnologies Inc Composiciones y sus usos en el tratamiento de infecciones virales.
US20140328876A1 (en) 2011-11-18 2014-11-06 Variation Biotechnologies Inc. Synthetic derivatives of mpl and uses thereof
WO2013104995A2 (en) 2012-01-12 2013-07-18 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CN104244984B (zh) 2012-01-27 2020-03-31 变异生物技术公司 用于治疗剂的方法和组合物
KR102277089B1 (ko) 2019-12-19 2021-07-14 에스케이바이오사이언스(주) A형 간염 바이러스의 제조방법 및 상기의 방법에 따라 제조된 a형 간염 바이러스

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2398504A1 (fr) 1977-07-29 1979-02-23 Tours Inst Virologie Culture de virus de l'hepatite a, in vitro. application a la production d'un antigene reactif, d'immunserums specifiques et de vaccins contre l'hepatite a
US4636469A (en) 1982-04-07 1987-01-13 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Isolation of hepatitis A virus strain HM-175
US4894228A (en) 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
US4620978A (en) 1982-04-07 1986-11-04 The United States Of America As Represented By The Department Of Health And Human Services Hepatitis A virus purified and triply cloned
US4532215A (en) 1982-04-07 1985-07-30 The United States Of America As Represented By The Department Of Health And Human Services Isolation of hepatitis A virus strain HM-175
US5516630A (en) 1983-09-30 1996-05-14 The United States Of America As Represented By The Department Of Health And Human Services Methods of detecting hepatitis A virus
US4783407A (en) * 1985-09-30 1988-11-08 Merck & Co., Inc. Growth of hepatitus A virus in vero cells
GB8800100D0 (en) * 1988-01-05 1988-02-10 Almond J W Attenuated viruses
DK0542949T3 (da) * 1991-05-08 1998-12-07 Schweiz Serum & Impfinst Hepatitis A-virusstamme, fremgangsmåde til isolering af nævnte virusstammer og hepatitis A-vacciner

Also Published As

Publication number Publication date
EP0666751A1 (en) 1995-08-16
US6180110B1 (en) 2001-01-30
CA2144317C (en) 2004-08-03
ATE205536T1 (de) 2001-09-15
JPH08504094A (ja) 1996-05-07
US6423318B1 (en) 2002-07-23
JP3523646B2 (ja) 2004-04-26
WO1994006446A1 (en) 1994-03-31
HK1013667A1 (en) 1999-09-03
ES2164074T3 (es) 2002-02-16
CA2144317A1 (en) 1994-03-31
DE69330758T2 (de) 2002-07-04
AU687012B2 (en) 1998-02-19
NZ256278A (en) 1996-11-26
EP0666751A4 (en) 1996-04-24
PT666751E (pt) 2002-01-30
US6113912A (en) 2000-09-05
AU4858593A (en) 1994-04-12
EP0666751B1 (en) 2001-09-12
SG73999A1 (en) 2000-07-18
US6680060B2 (en) 2004-01-20
US20020176869A1 (en) 2002-11-28
DE69330758D1 (de) 2001-10-18

Similar Documents

Publication Publication Date Title
DK0666751T3 (da) Mutanter af hepatitis A-virus, stamme HM-175, til anvendelse som hepatitis A-vacciner
Barnett et al. Further studies on the early protective responses of pigs following immunisation with high potency foot and mouth disease vaccine
CZ203195A3 (en) Method of cultivating a virus of a reproductive and respiratory syndrome of pigs and its use in vaccines
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
NZ226332A (en) Vaccine comprising transmissible gastroenteritis virus of swine for preventing canine coronavirus infection in dogs and process for preparation thereof
AU7763294A (en) Live in ovo vaccine
US4556556A (en) Vaccine for the prevention of vesicular stomatitis virus infection
NO950483L (no) Vaksine mot hepatitt-A
CN101757619A (zh) 兽用狂犬病灭活疫苗及其制备方法
DK0833903T3 (da) Multivalent vaccine mod bovint coronavirus og fremgangsmåde til behandling af infektioner forårsaget af bovint coronavirus
FI86376C (fi) Foerfarande foer framstaellning av renad och tre gaonger klonad hepatitis-a-virus.
Lopez et al. Immune response to foot-and-mouth disease virus in an experimental murine model II. Basis of persistent antibody reaction
DE3853736T2 (de) Staupevirus-Impfstoff.
PT603386E (pt) Imunizacao parenterica contra rotavirus
AR009650A1 (es) Mycoplasma synoviae atenuado vivo, su uso, un cultivo microbiologico que lo comprende, una vacuna bacteriana atenuada viva para la proteccion de las aves de corral contra la infeccion por mycoplasma synoviae y un metodo para preparar dicha vacuna.
ES2066206T3 (es) Utilizacion de adenilciclasa como vacunas contra bordetella.
DK52783A (da) Vaccine indeholdende en ozon-inaktiveret mikroorganisme og fremgangsmaade til fremstilling af en saadan vaccine
DK506979A (da) Vaccine mod infektioes katte-peritonitis og fremgangsmaade til dens fremstilling
NL300073I1 (nl) Vaccin.
RU94031386A (ru) Вакцина сухая культуральная против вирусного энтерита гусей и способ профилактики и лечения вирусного энтерита гусей
JPS56115724A (en) Prophilaxis and remedy for avian infectious coryza
Khodzhaev A study of the postvaccination immunity of guinea pigs repeatedly inoculated with a strain of brucella melitensis: Communication II
EP0178928A3 (en) Vaccines
Hendriksen Vaccine development: past, present and future
NO884921L (no) Fremgangsmaate for fremstilling av valpesyke-vaksine.